Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 16 | 2023 | 131 | 4.630 |
Why?
|
| HIV Infections | 12 | 2024 | 5097 | 1.400 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 146 | 1.210 |
Why?
|
| Hypertension | 2 | 2023 | 419 | 1.000 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 2 | 0.880 |
Why?
|
| South Africa | 22 | 2024 | 7596 | 0.750 |
Why?
|
| Female | 21 | 2024 | 9103 | 0.750 |
Why?
|
| Humans | 25 | 2024 | 14537 | 0.650 |
Why?
|
| Obesity | 2 | 2023 | 367 | 0.640 |
Why?
|
| Neoplasms | 4 | 2023 | 147 | 0.620 |
Why?
|
| Middle Aged | 11 | 2024 | 3601 | 0.590 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 266 | 0.560 |
Why?
|
| Prevalence | 4 | 2024 | 1192 | 0.460 |
Why?
|
| Aged | 5 | 2024 | 1740 | 0.350 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 43 | 0.350 |
Why?
|
| Survival Analysis | 2 | 2021 | 149 | 0.330 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 19 | 0.290 |
Why?
|
| Prospective Studies | 5 | 2024 | 1160 | 0.290 |
Why?
|
| Adult | 7 | 2024 | 5913 | 0.280 |
Why?
|
| Cohort Studies | 4 | 2022 | 967 | 0.250 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2023 | 7 | 0.240 |
Why?
|
| Tamoxifen | 2 | 2023 | 9 | 0.240 |
Why?
|
| Male | 5 | 2024 | 6754 | 0.240 |
Why?
|
| Multimorbidity | 2 | 2023 | 42 | 0.230 |
Why?
|
| Chronic Disease | 2 | 2023 | 107 | 0.230 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 468 | 0.230 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 5 | 0.220 |
Why?
|
| Radiation Oncology | 1 | 2024 | 2 | 0.220 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 163 | 0.220 |
Why?
|
| Hospital Mortality | 2 | 2021 | 95 | 0.210 |
Why?
|
| Age Factors | 3 | 2019 | 370 | 0.210 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 4 | 0.200 |
Why?
|
| Leukopenia | 1 | 2023 | 4 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 50 | 0.200 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2023 | 9 | 0.200 |
Why?
|
| Risk Factors | 2 | 2024 | 1475 | 0.190 |
Why?
|
| Terminal Care | 2 | 2020 | 35 | 0.190 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 77 | 0.190 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 31 | 0.180 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 14 | 0.180 |
Why?
|
| Receptors, Progesterone | 2 | 2021 | 14 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 17 | 0.180 |
Why?
|
| Inosine Monophosphate | 1 | 2021 | 3 | 0.180 |
Why?
|
| Retrospective Studies | 1 | 2024 | 799 | 0.180 |
Why?
|
| Breast | 2 | 2021 | 10 | 0.170 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 53 | 0.170 |
Why?
|
| Odds Ratio | 1 | 2021 | 133 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2021 | 151 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 253 | 0.160 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.150 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 353 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 62 | 0.150 |
Why?
|
| Urban Population | 1 | 2021 | 257 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2019 | 62 | 0.150 |
Why?
|
| Self Report | 1 | 2019 | 114 | 0.150 |
Why?
|
| Death | 1 | 2019 | 14 | 0.150 |
Why?
|
| Comorbidity | 1 | 2019 | 188 | 0.150 |
Why?
|
| Terminally Ill | 1 | 2019 | 21 | 0.150 |
Why?
|
| Risk Assessment | 1 | 2019 | 225 | 0.140 |
Why?
|
| Streptococcus pneumoniae | 1 | 2021 | 336 | 0.140 |
Why?
|
| Hospitalization | 1 | 2021 | 418 | 0.140 |
Why?
|
| Viral Load | 1 | 2022 | 819 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 14 | 0.140 |
Why?
|
| Age of Onset | 1 | 2018 | 32 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 411 | 0.140 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 3 | 0.130 |
Why?
|
| Mastectomy | 1 | 2017 | 10 | 0.130 |
Why?
|
| Rural Population | 1 | 2021 | 654 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 551 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2021 | 1748 | 0.130 |
Why?
|
| Infant | 1 | 2021 | 2244 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 33 | 0.090 |
Why?
|
| Genotype | 2 | 2023 | 442 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2023 | 480 | 0.090 |
Why?
|
| Palliative Care | 2 | 2020 | 52 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1422 | 0.060 |
Why?
|
| Medical Assistance | 1 | 2023 | 8 | 0.050 |
Why?
|
| Filgrastim | 1 | 2023 | 4 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 9 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 10 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 45 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 176 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2023 | 99 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 38 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 198 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 51 | 0.040 |
Why?
|
| United States | 1 | 2021 | 132 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2021 | 8 | 0.040 |
Why?
|
| Developing Countries | 1 | 2023 | 400 | 0.040 |
Why?
|
| Research Report | 1 | 2021 | 11 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 11 | 0.040 |
Why?
|
| Pain | 1 | 2020 | 41 | 0.040 |
Why?
|
| Attitude to Death | 1 | 2019 | 6 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 177 | 0.030 |
Why?
|
| Caregivers | 1 | 2019 | 76 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 370 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 96 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 199 | 0.030 |
Why?
|